Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
Disease burden
Immunization
Influenza
Risk groups
South Africa
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
02 06 2020
02 06 2020
Historique:
received:
24
12
2019
revised:
17
04
2020
accepted:
18
04
2020
pubmed:
12
5
2020
medline:
28
4
2021
entrez:
12
5
2020
Statut:
ppublish
Résumé
Data on influenza burden in risk groups for severe influenza are important to guide targeted influenza immunization, especially in resource limited settings. However, this information is limited overall and in particular in low- and middle-income countries. We sought to assess the mean annual national burden of medically and non-medically attended influenza-associated mild, severe-non-fatal and fatal illness among potential target groups for influenza immunization in South Africa during 2013-2015. We used published mean national annual estimates of mild, severe-non-fatal, and fatal influenza-associated illness in South Africa during 2013-2015 and estimated the number of such illnesses occurring among the following risk groups: (i) children aged 6-59 months; (ii) individuals aged 5-64 years with HIV, and/or pulmonary tuberculosis (PTB), and/or selected underlying medical conditions (UMC); (iii) pregnant women; and (iv) individuals aged ≥65 years. We also estimated the number of individuals among the same risk groups in the population. During 2013-2015, individuals in the selected risk groups accounted for 45.3% (24,569,328/54,086,144) of the population and 43.5% (4,614,763/10,598,138), 86.8% (111,245/128,173) and 94.5% (10,903/11,536) of the mean annual estimated number of influenza-associated mild, severe-non-fatal and fatal illness episodes, respectively. The rates of influenza-associated illness were highest in children aged 6-59 months (23,983 per 100,000 population) for mild illness, in pregnant women (930 per 100,000 population) for severe-non-fatal illness and in individuals aged ≥65 years (138 per 100,000 population) for fatal illness. Influenza immunization of the selected risk groups has the potential to prevent a substantial number of influenza-associated severe illness. Nonetheless, because of the high number of individuals at risk, South Africa, due to financial resources constrains, may need to further prioritize interventions among risk populations. Cost-burden and cost-effectiveness estimates may assist with further prioritization.
Sections du résumé
BACKGROUND
Data on influenza burden in risk groups for severe influenza are important to guide targeted influenza immunization, especially in resource limited settings. However, this information is limited overall and in particular in low- and middle-income countries. We sought to assess the mean annual national burden of medically and non-medically attended influenza-associated mild, severe-non-fatal and fatal illness among potential target groups for influenza immunization in South Africa during 2013-2015.
METHODS
We used published mean national annual estimates of mild, severe-non-fatal, and fatal influenza-associated illness in South Africa during 2013-2015 and estimated the number of such illnesses occurring among the following risk groups: (i) children aged 6-59 months; (ii) individuals aged 5-64 years with HIV, and/or pulmonary tuberculosis (PTB), and/or selected underlying medical conditions (UMC); (iii) pregnant women; and (iv) individuals aged ≥65 years. We also estimated the number of individuals among the same risk groups in the population.
RESULTS
During 2013-2015, individuals in the selected risk groups accounted for 45.3% (24,569,328/54,086,144) of the population and 43.5% (4,614,763/10,598,138), 86.8% (111,245/128,173) and 94.5% (10,903/11,536) of the mean annual estimated number of influenza-associated mild, severe-non-fatal and fatal illness episodes, respectively. The rates of influenza-associated illness were highest in children aged 6-59 months (23,983 per 100,000 population) for mild illness, in pregnant women (930 per 100,000 population) for severe-non-fatal illness and in individuals aged ≥65 years (138 per 100,000 population) for fatal illness.
CONCLUSION
Influenza immunization of the selected risk groups has the potential to prevent a substantial number of influenza-associated severe illness. Nonetheless, because of the high number of individuals at risk, South Africa, due to financial resources constrains, may need to further prioritize interventions among risk populations. Cost-burden and cost-effectiveness estimates may assist with further prioritization.
Identifiants
pubmed: 32389494
pii: S0264-410X(20)30539-9
doi: 10.1016/j.vaccine.2020.04.045
pmc: PMC7870979
mid: NIHMS1664185
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
4288-4297Subventions
Organisme : NCIRD CDC HHS
ID : U51 IP000155
Pays : United States
Organisme : NCIRD CDC HHS
ID : U51 IP000528
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Open Forum Infect Dis. 2019 Mar 19;6(3):ofz020
pubmed: 30906797
Influenza Other Respir Viruses. 2018 Jan;12(1):30-37
pubmed: 29243402
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
N Engl J Med. 2014 Sep 4;371(10):918-31
pubmed: 25184864
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Influenza Other Respir Viruses. 2018 Jan;12(1):46-53
pubmed: 29243406
Influenza Other Respir Viruses. 2019 Sep;13(5):484-495
pubmed: 31187609
Clin Infect Dis. 2014 May;58(9):1241-9
pubmed: 24567249
Vaccine. 2019 Jan 3;37(1):25-33
pubmed: 30471956
Open Forum Infect Dis. 2017 Feb 10;4(1):ofw262
pubmed: 28480255
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897
PLoS One. 2014 Aug 18;9(8):e105543
pubmed: 25133576
Vaccine. 2007 Jun 28;25(27):5086-96
pubmed: 17544181
Influenza Other Respir Viruses. 2018 Jan;12(1):38-45
pubmed: 29197152
Influenza Other Respir Viruses. 2018 May;12(3):360-373
pubmed: 29210203
Lancet Infect Dis. 2015 Sep;15(9):1066-1076
pubmed: 26112077
Influenza Other Respir Viruses. 2018 Nov;12(6):695-705
pubmed: 30120818
Clin Infect Dis. 2019 Aug 30;69(6):1036-1048
pubmed: 30508065
Influenza Other Respir Viruses. 2019 Mar;13(2):138-147
pubmed: 30596225
PLoS One. 2015 Jun 15;10(6):e0129173
pubmed: 26076197
BMC Public Health. 2014 Jan 16;14:41
pubmed: 24433304
Emerg Infect Dis. 2013 Nov;19(11):1766-74
pubmed: 24209781
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
Emerg Infect Dis. 2015 Apr;21(4):600-8
pubmed: 25811455
BMC Infect Dis. 2015 Jan 27;15:26
pubmed: 25623944
Clin Infect Dis. 2015 Oct 1;61(7):1063-70
pubmed: 26060287
PLoS One. 2015 Mar 18;10(3):e0118884
pubmed: 25786103
N Engl J Med. 2008 Oct 9;359(15):1555-64
pubmed: 18799552
Vaccine. 2017 Jan 23;35(4):521-528
pubmed: 28024955
J Infect Dis. 2012 Dec 15;206 Suppl 1:S1-4
pubmed: 23169953
Clin Infect Dis. 2019 Feb 15;68(5):773-780
pubmed: 29961814
Vaccine. 2016 Nov 4;34(46):5649-5655
pubmed: 27720448
BMC Infect Dis. 2016 Dec 13;16(1):757
pubmed: 27964716